EPHX4 and neoplasm: Finally, the lower Immune Profile Score (IPS) observed in the high EPHX4 expression group indicates that EPHX4 could impact tumor immune evasion mechanisms, potentially reducing responses to anti-CTLA-4 and anti-PD-1 therapies.